BA
AMPH icon

Boston Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Boston Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$840K Sell
42,365
-2,848
-6% -$59.3K 0.04% 404
2019
Q2 		$954K Sell
45,213
-397
-0.9% -$8.3K 0.05% 366
2019
Q1 		$932K Sell
45,610
-2,551
-5% -$57.2K 0.05% 356
2018
Q4 		$958K Buy
48,161
+3,945
+9% +$77.8K 0.06% 321
2018
Q3 		$851K Buy
44,216
+2,268
+5% +$40.4K 0.04% 407
2018
Q2 		$640K Sell
41,948
-705
-2% -$12.3K 0.02% 454
2018
Q1 		$800K Buy
42,653
+2,733
+7% +$51.4K 0.02% 409
2017
Q4 		$768K Buy
39,920
+1,025
+3% +$19.1K 0.02% 422
2017
Q3 		$695K Buy
38,895
+3,635
+10% +$59.8K 0.02% 426
2017
Q2 		$630K Sell
35,260
-2,080
-6% -$33K 0.01% 445
2017
Q1 		$541K Buy
37,340
+6,700
+22% +$105K 0.01% 450
2016
Q4 		$564K Buy
30,640
+14,735
+93% +$287K 0.01% 455
2016
Q3 		$302K Buy
+15,905
New +$289K 0.01% 607

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boston Advisors's AMPH Position: Q3 2019 in Review

Boston Advisors reduced its Amphastar Pharmaceuticals (AMPH) stake by 6.3% in Q3 2019, selling an estimated $59.3K and leaving 42,365 shares worth $840K. The position accounts for 0.04% of the portfolio, ranked #404.

Boston Advisors first reported a position in AMPH in Q3 2016 and has held it in 13 quarters since. The position peaked at $958K in Q4 2018. 134 funds tracked by Wall St. Rank hold AMPH as of Q3 2019.

  • Boston Advisors held 42,365 shares of Amphastar Pharmaceuticals worth $840K as of Q3 2019.
  • Boston Advisors sold 2,848 Amphastar Pharmaceuticals shares in Q3 2019, an estimated $59.3K.
  • Amphastar Pharmaceuticals made up 0.04% of Boston Advisors's portfolio in Q3 2019, its #404 holding.
  • Boston Advisors first reported a position in Amphastar Pharmaceuticals in Q3 2016 and has held it in 13 quarters since.
  • Boston Advisors's Amphastar Pharmaceuticals position peaked at $958K in Q4 2018.
  • 134 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.